HPV疫苗接种与初筛可缩小新西兰宫颈癌差距
该建模研究基于新西兰HPV疫苗接种与宫颈筛查模型,按族裔拟合观察数据,评估从细胞学筛查转为5年一次HPV初筛及疫苗接种对毛利女性与其他女性宫颈癌发病率的影响。结果显示两种干预对毛利女性的相对降幅更大,但在当前参与水平下毛利女性长期发病率仍近两倍于欧洲/其他女性。
要点
- 从细胞学转为HPV初筛预计使毛利女性宫颈癌发病率降低17%,欧洲/其他女性降低14%。
- 疫苗接种与HPV初筛联合使毛利女性发病率降低58%,欧洲/其他女性降低44%。
- 当前参与水平下毛利女性长期发病率仍近两倍(6.1/10万 vs 3.1/10万)。
核心结论
- 疫苗接种和HPV初筛对毛利女性的相对降幅大于欧洲/其他女性,但毛利女性宫颈癌发病率仍将更高。
研究设计与样本
- 采用已建立的新西兰HPV疫苗接种与宫颈筛查模型,按族裔拟合观察数据,进行长期影响预测。
主要发现
- 疫苗接种覆盖率毛利女性63% vs 欧洲/其他女性47%,5年筛查覆盖率毛利女性68% vs 欧洲/其他女性81%。
- 从细胞学转为HPV初筛预计发病率降低:毛利女性17%,欧洲/其他女性14%。
- 疫苗与HPV初筛联合预计发病率降低:毛利女性58%,欧洲/其他女性44%。
- 当前参与水平下长期发病率:毛利女性6.1/10万 vs 欧洲/其他女性3.1/10万。
- 在所考察策略中,高疫苗覆盖和筛查异常监测中毛利女性更高参与度影响最大。
临床怎么用
- 模型提示提高疫苗覆盖和筛查异常监测中毛利女性参与度对降低宫颈癌发病率影响最大。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical cancer rates are over twice as high, and screening coverage is lower, in Māori women compared to other women in New Zealand, whereas uptake of HPV vaccine is higher in Maori females. We aimed to assess the impact of HPV vaccination and the proposed transition to 5-yearly primary HPV screening in Māori and other women in New Zealand, at current participation levels; and additionally to investigate which improvements to participation in Māori females (in vaccination, screening, or surveillance for screening-defined higher-risk women) would have the greatest impact on cervical cancer incidence/mortality. METHODS: An established model of HPV vaccination and cervical screening in New Zealand was adapted to fit observed ethnicity-specific data. Ethnicity-specific models were used to estimate the long-term impact of vaccination and screening (vaccination coverage 63% vs 47%; five-year screening coverage 68% vs 81% in Maori vs European/Other women, respectively). RESULTS: Shifting from cytology to HPV-based screening is predicted to reduce cervical cancer incidence by 17% (14%) in Maori (European/Other) women, respectively. The corresponding reductions due to vaccination and HPV-based screening combined were 58% (44%), but at current participation levels long-term incidence would remain almost twice as high in Māori women (6.1/100,000 compared to 3.1/100,00 in European/Other women). Among strategies we examined, the greatest impact came from high vaccine coverage and achieving higher attendance by Māori women under surveillance for screen-detected abnormalities. CONCLUSION: Relative reductions in cervical cancer due to vaccination and HPV-based screening are predicted to be greater in Maori than in European/Other women. While these interventions have the potential to substantially reduce between-group differences, cervical cancer incidence would remain higher in Maori women. These findings highlight the importance of multiple approaches and the potential influence of factors beyond HPV prevention.
引用
- Smith MA, Hall M, Lew JB, et al. Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. Vaccine. 2018. PMID: 30224201. doi:10.1016/j.vaccine.2018.08.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。